Simone Saibeni
Overview
Explore the profile of Simone Saibeni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
1258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Bernardi A, Bezzio C, Puricelli M, Gilardi D, Saibeni S
J Clin Med
. 2025 Jan;
14(2).
PMID: 39860594
Despite the increasing number of available medications, a significant proportion of IBD patients fail to achieve the current therapeutic targets. Uncontrolled IBD has a significant impact on patients' quality of...
2.
Farkas B, Bessissow T, Limdi J, Sethi-Arora K, Kagramanova A, Knyazev O, et al.
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768726
: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn's disease (CD) are limited. : We conducted a multicentre, retrospective study...
3.
Bezzio C, Brinch D, Ribaldone D, Cappello M, Ruzzon N, Vernero M, et al.
Nutrients
. 2024 Dec;
16(23).
PMID: 39683376
Introduction: The prevalences of malnutrition and sarcopenia in patients with IBD are not precisely known, and nutritional assessment is not standardized. We assessed the prevalence and risk factors of these...
4.
Bezzio C, Cavalli C, Franchellucci G, Dal Buono A, Gabbiadini R, Scalvini D, et al.
Therap Adv Gastroenterol
. 2024 Nov;
17:17562848241299564.
PMID: 39575159
Inflammatory bowel diseases (IBD) and psoriasis are chronic inflammatory conditions belonging to the heterogeneous group of immune-mediated inflammatory diseases (IMIDs). A significant bidirectional link between these two entities has been...
5.
Bezzio C, Franchellucci G, Savarino E, Mastronardi M, Caprioli F, Bodini G, et al.
Crohns Colitis 360
. 2024 Nov;
6(4):otae060.
PMID: 39525291
No abstract available.
6.
Goren I, Fallek Boldes O, Boldes T, Knyazev O, Kagramanova A, Limdi J, et al.
J Crohns Colitis
. 2024 Oct;
PMID: 39435855
Objectives: Elderly hospitalized patients with inflammatory bowel disease (IBD) flare and concurrent Clostridioides difficile infection (CDI) are considered at high risk of IBD-related complications. We aimed to evaluate the short,...
7.
Pessarelli T, Topa M, Sorge A, Nandi N, Pugliese D, Macaluso F, et al.
Nutrients
. 2024 Oct;
16(19).
PMID: 39408277
Background/objectives: Limited data exist on the epidemiology and clinical management of short bowel syndrome (SBS) and chronic intestinal failure (CIF) in Crohn's disease (CD). This study aimed to evaluate these...
8.
Ammirata G, Arigoni M, Licastro D, Caviglia G, Disabato M, Zubair G, et al.
Antioxidants (Basel)
. 2024 Sep;
13(9).
PMID: 39334706
The relationship between serum 25-hydroxyvitamin D (25(OH)D) levels, genomic response to vitamin D (Vit.D), and positivity to SARS-CoV-2 remains understudied. In this pilot study, during the follow-up of patients with...
9.
Calabrese E, Onali S, Variola A, Ribaldone D, Savarino E, Viola A, et al.
Dig Liver Dis
. 2024 Sep;
57(1):241-250.
PMID: 39299813
Background And Aim: Suboptimal disease control (SDC) and its contributing factors in IBD according to STRIDE-II criteria is unclear. IBD-PODCAST was a non-interventional, international, multicenter real-world study to assess this....
10.
DAmico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, et al.
Eur J Clin Invest
. 2024 Jul;
54(11):e14283.
PMID: 38979834
Background And Aims: Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of...